http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Nguyen Ngoc Nha Thao (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Nguyen Ngoc Nha Thao,Pham Duy Toan,Nguyen Duc Tuan,Trinh Thi Thu Loan 한국약제학회 2021 Journal of Pharmaceutical Investigation Vol.51 No.5
Purpose Diabetes mellitus, especially type II, is one of the most common chronic diseases. Its first-line oral treatment is metformin, commonly in combination with another agent such as sitagliptin, a dipeptidyl peptidase-4 inhibitor. The commercial combination is Janumet XR 50/500 mg, in which the extended-release metformin core tablet is coated with an immediaterelease layer of sitagliptin. However, the coating process with solvents and a high temperature might affect the sitagliptin properties and product quality. Hence, the present study aimed to develop bilayer matrix tablets incorporating both drugs into two separate layers, a sustained-release metformin layer, and an immediate-release sitagliptin layer. Methods Wet granulation and direct compression methods were used for the metformin and sitagliptin layer, respectively. The optimal formulation was selected and characterized based on the design of experiments method. In vitro release and in vivo bioequivalence studies were also conducted to compare with the reference Janumet XR 50/500 mg. Results The optimized formulation immediately released sitagliptin (> 95%) within 30 min at pH 1.2 and sustained the release metformin for 10 h at pH 6.8. The in vivo behaviors of the bilayer tablets were bioequivalent to the commercial product, Janumet XR 50/500 mg. Conclusion The bilayer tablets could provide an alternative approach for combination therapy of type II diabetes.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
